ESMO ban 728x90


Thursday September 28th


8.30-10.00 Session I:
François-Xavier DANLOS/Sophie POSTEL-VINAY

  8.30-9.00: Exploiting self-inflicted DNA breaks to evade growth limits imposed by genotoxic stress
Dr Claus Sørensen, University of Copenhagen, D

  9.00-9.30: Chromosomal instability-induced inflammation: a catch 22 for cancer cells
Dr Floris Foijer, University of Groningen, NL

  9.30-10.00: A new role of altered R-loop homeostasis in radiation-induced tumor immunogenicity
Pr Sandra Demaria, Weill Cornell Medicine, USA

  10.00-10.30 Coffee break


  10.30-12.30 Session II:

  10.30-11.00: Myeloid cells in cancer
Dr Mikael Pittet, University of Geneva, SW

  11.00-11.30: Neutrophils in lung cancer: modulators of tumor growth and therapy response
Dr Etienne Meylan, Université Libre de Bruxelles, B

  11.30-12.00: Local and abscopal responses of small-cell lung cancer to radiation therapy
Pr Julien Sage, Stanford University, USA

  12.00-12.30: Enhancing phagocytosis to magnify radiotherapy-induced in situ tumor vaccination
Dr Rodney Cheng-En Hsieh, Chang Gung Memorial Hospital, Taiwan

  12.30-14.00 Lunch break and exhibition


14.00-16.00: Session III:
Pierre-Antoine LAURENT/Céline MIRJOLET

  14.00-14.30: Spatially fractionated FLASH radiotherapy modulates the antitumor immune response
Dr Cristian Fernandez-Palomo, University of Bern, SW

  14.30-15.00: Radiotherapy with carbon ions plus CTLA4 blockade elicits therapeutic immune responses in a murine tumor model
Dr Stefan Eichmuller, DKFZ Heidelberg, G

  15.00-15.30: Revisiting the radiobiology of targeted alpha therapy
Dr Jean-Pierre Pouget, Institut de Recherche en Cancérologie de Montpellier, FR

  15.30-16.00: Radiotherapy in the context of multimodality treatment for oligometastatic disease
Pr Matthias Guckenberger, University of Zurich, SW

  16.00-16.30 coffee break


  16.30-18.00 Session IV:

  16.30-17.00: IL-1, CAFs and rectal cancer
Dr Florian Greten, Frankfurt University, G

  17.00-17.30: Innovative approaches to trigger radiation induced immunological cell death and overcome checkpoint resistance
Pr Jim Welsh, MD Anderson Cancer Center, USA

Keynote Presentation

  17.30-18.15: Barriers that hinder immune response in the irradiated tumor: an insurmountable challenge or opportunity for innovation?
Pr Ralph Weichselbaum, University of Chicago, USA

Cookie Policy

This website uses cookies that are necessary to its functioning and required to achieve the purposes illustrated in the privacy policy. By accepting this OR scrolling this page OR continuing to browse, you agree to our privacy policy.